PA
IHE icon

Prism Advisors’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Prism Advisors’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$208K Hold
2,108
– – 0.05% 76
2026
Q2 		$209K Buy
+2,108
New +$190K 0.05% 70

Other funds holding IHE

CCA
Cadent Capital Advisors Tulsa, Oklahoma $466M AUM 30.56% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VWM
Valley Wealth Managers Paramus, New Jersey $1.76B AUM 33.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return

Prism Advisors's IHE Position: Q3 2026 in Review

Prism Advisors held its iShares US Pharmaceuticals ETF (IHE) position steady in Q3 2026 at 2,108 shares worth $208K. The position accounts for 0.05% of the portfolio, ranked #76.

Prism Advisors first reported a position in IHE in Q2 2026 and has held it in 2 quarters since. The position peaked at $209K in Q2 2026. 7 funds tracked by Wall St. Rank hold IHE as of Q3 2026.

  • Prism Advisors held 2,108 shares of iShares US Pharmaceuticals ETF worth $208K as of Q3 2026.
  • Prism Advisors left its iShares US Pharmaceuticals ETF share count unchanged in Q3 2026.
  • iShares US Pharmaceuticals ETF made up 0.05% of Prism Advisors's portfolio in Q3 2026, its #76 holding.
  • Prism Advisors first reported a position in iShares US Pharmaceuticals ETF in Q2 2026 and has held it in 2 quarters since.
  • Prism Advisors's iShares US Pharmaceuticals ETF position peaked at $209K in Q2 2026.
  • 7 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q3 2026.

Based on Prism Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.